Immunogenicity of 13-valent pneumococcal conjugate vaccine in pediatric patients with inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 21, Issue 7, 2015, Pages 1607-1614

  Banaszkiewicz, Aleksandra ^a   Targońska, Brygida ^b   Kowalska Duplaga, Kinga ^c   Karolewska Bochenek, Katarzyna ^a   Sieczkowska, Agnieszka ^d   Gawrońska, Agnieszka ^a   Grzybowska Chlebowczyk, Urszula ^e   Krzesiek, Elzbieta ^f   Łazowska Przeorek, Izabella ^a   Kotowska, Maria ^a   Sienkiewicz, Edyta ^a   Walkowiak, Jarosław ^b   Gregorek, Hanna ^g   Radzikowski, Andrzej ^a   Albrecht, Piotr ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^d MEDICAL UNIVERSITY OF GDANSK   (Poland)

^e MEDICAL UNIVERSITY OF SILESIA   (Poland)

^f WROCLAW MEDICAL UNIVERSITY   (Poland)

^g CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

Author keywords

Crohn's disease; immune response; PCV; ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; IMMUNOGLOBULIN G; INFLIXIMAB; MERCAPTOPURINE; PNEUMOCOCCUS VACCINE; STEROID; IMMUNOLOGIC FACTOR;

ADOLESCENT; ADULT; ANTIBODY TITER; ARTICLE; CHILD; CHILL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG RESPONSE; DRUG SAFETY; EVALUATION STUDY; FATIGUE; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEROTYPE; STEROID THERAPY; CLINICAL TRIAL; FOLLOW UP; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; PRESCHOOL CHILD; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPTAVALENT PNEUMOCOCCAL CONJUGATE VACCINE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; MALE; PROSPECTIVE STUDIES; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

EID: 84932185444     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000406     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention. Pneumococcal Disease Epidemiology and Prevention of Vaccine-preventable Diseases the Pink Book: Course Textbook. 12th Edition Second Printing. 2012;7. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/pneumo.html Accessed December 4, 2014.
2. File TM Jr. Streptococcus pneumoniae and community-Acquired pneumonia: a cause for concern. Am J Med. 2004;117(suppl 3A):39S-50S.
3. Rozenbaum MH, Pechlivanoglou P, van der Werf TS, et al. The role of Streptococcus pneumoniae in community-Acquired pneumonia among adults in Europe: a meta-Analysis. Eur J Clin Microbiol Infect Dis. 2013;32:305-316.
4. Senstad AC, Suren P, Brauteset L, et al. Community-Acquired pneumonia (CAP) in children in Oslo, Norway. Acta Paediatr. 2009;98:332-336.
5. Clark JE, Hammal D, Hampton F, et al. Epidemiology of communityacquired pneumonia in children seen in hospital. Epidemiol Infect. 2007; 135:262-269.
6. Weigl JA, Puppe W, Belke O, et al. Population-based incidence of severe pneumonia in children in Kiel, Germany. Klin Padiatr. 2005;217: 211-219.
7. Cevey-Macherel M, Galetto-Lacour A, Gervaix A, et al. Etiology of community-Acquired pneumonia in hospitalised children based on WHO clinical guidelines. Eur J Pediatr. 2009;168:1429-1436.
8. Pneumococcal vaccines WHO position paper-2012. Weekly Epidemiol Rec. 2012;87:129-144.
9. Herrlinger KR, Noftz MK, Dalhoff K, et al. Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission. Am J Gastroenterol. 2002;97:377-381.
10. Long MD, Martin C, Sandler RS, et al. Increased risk of pneumonia among patients with inflammatory bowel disease. Am J Gastroenterol. 2013;108:240-248.
11. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT™ registry. Am J Gastroenterol. 2012;107: 1409-1422.
12. Wasan SK, Baker SE, Skolnik PR, et al. A practical guide to vaccinating the inflammatory bowel disease patient. Am J Gastroenterol. 2010;105: 1231-1238.
13. Rubin LG, Levin MJ, Ljungman P, et al; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:309-318.
14. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468.
15. Jackson LA, Gurtman A, van Cleeff M, et al. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults. Vaccine. 2013;31:3577-3584.
16. Moberley S, Holden J, Tatham DP, et al. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev. 2013;1: CD000422.
17. Centers for Disease Control and Prevention (CDC). Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among children aged 6-18 years with immunocompromising conditions: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2013; 62:521-524.
18. Tomczyk S, Bennett NM, Stoecker C, et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged 65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822-825.
19. Melmed GY, Agarwal N, Frenck RW, et al. Immunosuppression impairs response to pneumococcal polysaccharide vaccination in patients with inflammatory bowel disease. Am J Gastroenterol. 2010;105:148-154.
20. Fiorino G, Peyrin-Biroulet L, Naccarato P, et al. Effects of immunosuppression on immune response to pneumococcal vaccine in inflammatory bowel disease: a prospective study. Inflamm Bowel Dis. 2012;18: 1042-1047.
21. Lee CK, Kim HS, Ye BD, et al; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on antitumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis. 2014;8:384-391.
22. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795-806.
23. World Health Organisation. Pneumococcal conjugate vaccines. Recommendations for the production and control of pneumococcal conjugate vaccines. WHO Tech Rep Ser. 2005;927:64-98.
24. Wernette CM, Frasch CE, Madore D, et al. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin Diagn Lab Immunol. 2003;10:514-519.
25. Concepcion NF, Frasch CE. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay. Clin Diagn Lab Immunol. 2001;8: 266-272.
26. Siber GR, Chang I, Baker S, et al. Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies. Vaccine. 2007; 25:3816-3826.
27. Rousseeuw PJ, Croux C. Alternatives to the median absolute deviation. J Am Stat Assoc. 1993;88:1273-1283.
28. Frenck R Jr, Thompson A, Senders S, et al. 13-valent pneumococcal conjugate vaccine in older children and adolescents either previously immunized with or nave to 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2014;33:183-189.
29. Bamford A, Kelleher P, Lyall H, et al. Serological response to 13-valent pneumococcal conjugate vaccine in children and adolescents with perinatally acquired HIV infection. AIDS. 2014;28:2033-2043.
30. Farmaki E, Kanakoudi-Tsakalidou F, Spoulou V, et al. The effect of anti-TNF treatment on the immunogenicity and safety of the 7-valent conjugate pneumococcal vaccine in children with juvenile idiopathic arthritis. Vaccine. 2010;28:5109-5113.
31. Lu Y, Jacobson DL, Ashworth LA, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol. 2009;104:444-453.
32. Mamula P, Markowitz JE, Piccoli DA, et al. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007;5:851-856.
33. Radzikowski A, Banaszkiewicz A, qazowska-Przeorek I, et al. Immunogenicity of hepatitis A vaccine in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:1117-1124.
34. Nielsen HJ, Mortensen T, Holten-Andersen M, et al. Increased levels of specific leukocyte-And platelet-derived substances during normal antitetanus antibody synthesis in patients with inactive Crohn disease. Scand J Gastroenterol. 2001;36:265-269.
35. Moses J, Alkhouri N, Shannon A, et al. Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab. Am J Gastroenterol. 2012;107:133-138.
36. Richter SS, Heilmann KP, Dohrn CL, et al. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011. Emerg Infect Dis. 2013;19:1074-1083.
37. Ruckinger S, von Kries R, Siedler A, et al. Association of serotype of Streptococcus pneumoniae with risk of severe and fatal outcome. Pediatr Infect Dis J. 2009;28:118-122.
38. Song JH, Dagan R, Klugman KP, et al. The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine. 2012;30: 2728-2737.